OR WAIT null SECS
Few, if any, subspecialties in cardiology have ever seen the explosion in knowledge and therapeutics the heart failure community has bore witness to in the last decade.
In recent years, while heart failure has been thrust into the spotlight and dominated late-breaking sessions at major organizations’ meetings, such as ESC Congress and the ACC annual meeting, the Heart Failure Society of America (HFSA) annual scientific meeting has become the hub for discussions around what many consider the most exciting area in cardiometabolic health at the moment. In years past, the focus of the HFSA meeting and others that have played host to late-breaking trial data and presentations has been on the data from within clinical trials. Now, with the efficacy and safety profiles established, the conversations have shifted to clinical processes and implementation of these therapies.
In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.